Compare CBFV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBFV | CRBU |
|---|---|---|
| Founded | 1901 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.1M | 192.4M |
| IPO Year | 2014 | 2021 |
| Metric | CBFV | CRBU |
|---|---|---|
| Price | $36.23 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $38.00 | $10.75 |
| AVG Volume (30 Days) | 1.8K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $43,557,000.00 | N/A |
| Revenue This Year | $48.93 | $1.63 |
| Revenue Next Year | $7.97 | $10.93 |
| P/E Ratio | $48.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.11 | $0.96 |
| 52 Week High | $37.75 | $3.53 |
| Indicator | CBFV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 67.29 |
| Support Level | $34.08 | $1.75 |
| Resistance Level | $36.44 | $2.97 |
| Average True Range (ATR) | 0.55 | 0.17 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 100.00 | 90.48 |
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.